BRISBANE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) — Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical firm advancing novel complement therapies for neuroinflammatory ailments of the physique, mind, and eye, right this moment introduced the strengthening of its senior management group with the appointment of Shikhar Agarwal, M.B.A. as senior vp, head of business, Sunil B. Mehta, Pharm.D as senior vp of medical affairs and Myoung Kim, PHD, M.A., M.B.A. as vp of well being economics and outcomes analysis.
We’re excited to welcome Shikhar, Sunil and Myoung to the Annexon household as we put together for industrial improvement of our flagship applications in Guillain-Barré Syndrome (GBS) and geographic atrophy (GA), mentioned Douglas Love, president and chief govt officer of Annexon. Attracting robust expertise with intensive expertise in growing successful product methods and main a number of the most profitable immunology product launches to-date is a win. These leaders will assist Annexon to appreciate the numerous market alternatives for our first-in-kind product candidates and permit us to realize our mission of aiding hundreds of thousands of sufferers which are impacted by devastating neuroinflammatory ailments.
Shikhar Agarwal, M.B.A. is a seasoned chief with over 20 years in pharmaceutical advertising, market entry, gross sales and industrial operations, and a monitor file of efficiently main portfolio technique, group construct and product launch execution throughout therapeutic areas. Previous to becoming a member of Annexon, he was vp, head of selling at argenx SE, the place he led the launch of VYVGART ® in Myasthenia Gravis and power inflammatory demyelinating polyradiculoneuropathy (CIDP), delivering $400 million in first 12 months income and reaching blockbuster standing in second 12 months of launch amidst a number of aggressive launches. Previous to that he held industrial roles of accelerating accountability at Amgen Inc (NASDAQ:). throughout market entry, advertising, gross sales and market analysis. Early in his profession, he labored as a senior marketing consultant at Proxicom, Inc., the place he developed industrial and analytical options for Fortune 500 purchasers. Mr. Agarwal holds an M.B.A. from UCLA Anderson College of Administration, and a B.S. from St. John’s School in Agra, India.
Sunil B. Mehta, Pharm.D. brings 20 years of medical affairs expertise together with efficiently constructing and main U.S. and international medical affairs groups and infrastructure for product launches and fostering robust relationships with key opinion leaders throughout a number of therapeutic areas, together with nephrology, hematology, uncommon neurological and autoimmune issues. Previous to becoming a member of Annexon, he served as vp and head of medical affairs at argenx the place he efficiently constructed and led extremely competent medical affairs groups by means of the launches of VYVGART in Myasthenia Gravis and CIDP. For nearly a decade Dr. Mehta additionally held varied roles of accelerating accountability at Alexion (NASDAQ:) in medical affairs and constructed the U.S. medical affairs groups in preparation of Myasthenia Gravis and neuromyelitis optica spectrum dysfunction launches. Previous to Alexion, he labored at Amgen in medical affairs roles of accelerating accountability. Dr. Mehta holds a Pharm.D. diploma from Rutgers College.
Myoung Kim, Ph.D., M.A., M.B.A. brings over 25 years of expertise in well being economics and outcomes analysis (HEOR) and observational analysis. Previous to Annexon, Dr. Kim was vp and head of U.S. HEOR, actual world proof and inhabitants well being at Novartis (SIX:), the place she led office- and field-teams spanning your entire portfolio. Previous to that she served the same function as vp of real-world worth and proof at Janssen Prescription drugs the place she led worth proof era and communication throughout the Janssen portfolio. Early in her profession she additionally held growing roles of accountability at J&J (NYSE:) Medical Gadgets and held positions at Bristol-Myers Squibb (NYSE:), Bayer (OTC:) Company, and Merck & Co. Dr. Kim holds a Ph.D. and an M.A. in well being economics and coverage from The Wharton College on the College of Pennsylvania. She additionally earned an M.B.A. of worldwide enterprise from the College of South Carolina and a B.A. from Seoul Nationwide College in Seoul, South Korea.
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is a biopharmaceutical firm advancing a late-stage medical platform of novel therapies for individuals residing with devastating classical complement-mediated neuroinflammatory ailments of the physique, mind, and eye. Annexon’s novel scientific method targets upstream C1q to dam the classical complement inflammatory cascade earlier than it begins, and its therapeutic candidates are designed to offer significant advantages throughout a number of autoimmune, neurodegenerative and ophthalmic ailments. With proof-of idea information in Guillain-Barré syndrome, Huntington’s illness and Geographic Atrophy, Annexon is rigorously advancing its mid-to late-stage medical trials to carry their potential therapies to sufferers as shortly as attainable. To be taught extra go to annexonbio.com.
Ahead Trying Statements
This press launch incorporates forward-looking statements throughout the that means of Part 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Alternate Act of 1934, as amended. In some instances, you may determine forward-looking statements by terminology corresponding to goal, anticipate, assume, imagine, ponder, proceed, might, design, due, estimate, anticipate, purpose, intend, could, goal, plan, positioned, potential, predict, search, ought to, recommend, goal, on monitor, will, would and different related expressions which are predictions of or point out future occasions and future tendencies, or the unfavorable of those phrases or different comparable terminology. All statements apart from statements of historic info contained on this press launch are forward-looking statements. These forward-looking statements embrace, however aren’t restricted to, the potential therapeutic good thing about ANX005 and ANX007, the power to commercialize flagship applications in Guillain-Barré Syndrome (GBS) and geographic atrophy (GA), and the power to appreciate the numerous market alternatives in these therapeutic areas. Ahead-looking statements aren’t ensures of future efficiency and are topic to dangers and uncertainties that would trigger precise outcomes and occasions to vary materially from these anticipated, together with, however not restricted to, dangers and uncertainties associated to: the corporate’s historical past of web working losses; the corporate’s potential to acquire mandatory capital to fund its medical applications; the early levels of medical improvement of the corporate’s product candidates; the results of public well being crises on the corporate’s medical applications and enterprise operations; the corporate’s potential to acquire regulatory approval of and efficiently commercialize its product candidates; any undesirable unintended effects or different properties of the corporate’s product candidates; the corporate’s reliance on third-party suppliers and producers; the outcomes of any future collaboration agreements; and the corporate’s potential to adequately keep mental property rights for its product candidates. These and different dangers are described in larger element below the part titled Danger Components contained within the firm’s Annual Report on Type 10-Ok and Quarterly Reviews on Type 10-Q and the corporate’s different filings with the SEC. Any forward-looking statements that the corporate makes on this press launch are made pursuant to the Non-public Securities Litigation Reform Act of 1995, as amended, and communicate solely as of the date of this press launch. Besides as required by legislation, the corporate undertakes no obligation to publicly replace any forward-looking statements, whether or not on account of new info, future occasions or in any other case.
Investor Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
Media Contact:
Sheryl Seapy
Actual Chemistry
949-903-4750
sseapy@realchemistry.com
